-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Bristol-Myers Squibb (BMS)-Pfizer Alliance recently issued a statement that the U.
According to the CAFC's ruling, the earliest time for a generic drug manufacturer to be allowed to launch its apixaban generic drug product is April 1, 2028, but this may depend on additional litigation and challenges
Eliquis is an oral anticoagulant discovered by BMS
Eliquis was approved for listing in the European Union and the United States in May 2011 and December 2012, respectively, and entered the Chinese market in January 2013
In the more than ten years since its launch, Eliquis has grown into a star product of BMS and Pfizer
Over the years, BMS and Pfizer have also been working hard to fight against generic drug manufacturers
BMS and Pfizer eventually reached a legal settlement with several of their competitors, including Mylan (now Huizhi) and Micro Labs.
The CAFC ruling is a good thing for the BMS-Pfizer alliance
Reference source:
Reference source:1.
1.
2.
Inventory of TOP15 drugs with patent expiration in the next ten years involves AbbVie, Merck, Pfizer, etc.